NCT03616587: Study of AZD9833 Alone or in Combination With Palbociclib in Women With Advanced Breast Cancer

NCT03616587
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have been on at least one line of endocrine therapy in the metastatic setting; No limit on endocrine therapies
Exclusions: Patients who have had more than 2 lines of chemotherapy for advanced disease
https://ClinicalTrials.gov/show/NCT03616587

Comments are closed.

Up ↑